This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Lesson of Allergan

03/18/14 - 07:17 PM EDT

Just over one year ago, when Allergan stood at about $115, worries abounded, causing the stock to drop to the low $80s by the middle of 2013, as the overall equity market continued to roar. This underperformance spooked many investors, but that low was a huge opportunity, as the stock has posted a stellar run ever since, now at new highs at over $130. I bring this up now because many are talking about a bubble in biotech, particularly given surges from recent IPOs.


The All Important Jobs Number

03/07/14 - 08:34 AM EST

All eyes are on the non-farm payroll numbers this morning, but take a look at some bizarre things happening in the U.S. economy right now


Hidden Camera Captures Debate Over Costco's Future

03/06/14 - 08:43 AM EST

Costco is down this morning on a disappointing report. Check out this hidden camera capturing a debate over Costco's drivers


Buy Amazon Here

03/05/14 - 05:28 PM EST

The company still hasn't recovered since its quarterly report. That is a gift and it is time to come into the stock


Honeywell: Why It's At All-Time Highs

03/05/14 - 05:24 PM EST

Honeywell has mastered a five year plan that works


Nat Gas Export: The Next Horizon

03/04/14 - 03:51 PM EST

The latest disruptions in Ukraine and Russia are merely another reason to push for natural gas export


Why Abercrombie is up this morning

02/26/14 - 09:37 AM EST

Forgiveness in retail is the story of the last five days. And with Abercrombie in particular, expectations came low enough to allow the stock to surge


This Week: The Retail Tell

02/24/14 - 08:48 PM EST

The effect of weather lingers, but we will get a sense of company standing from guidance


Biotech Continues to Lead Market: Innovation and M&A

02/18/14 - 10:35 PM EST

The big news of today was Actavis' announcement o buy Forest Labs for $25 billion. And this is much more than just another win for Carl Icahn, the second largest holder of Forest Labs, which has gotten a lot of focus in media outlets.


Online Travel Agencies: Secular Winners

02/13/14 - 10:42 AM EST

Want to try to game these as a trade? Don't try - they are long-term winners


Nicole Urken is Research Director of Mad Money and Jim Cramer's researcher at TheStreet. Nicole analyzes stocks and develops a strategic macro outlook, which she incorporates into segment ideas for CNBC's "Mad Money." Nicole also supports Jim's other endeavors including "Squawk on the Street,", and his latest best-selling book "Get Rich Carefully."

Previously, she worked as an investment banking analyst for the Industrials Group in Goldman Sachs' New York office. Born and raised in Princeton, New Jersey, Nicole graduated with honors from Harvard College, where she served as executive editor of The Harvard Crimson.


DOW 18,093.66 -109.71 -0.60%
S&P 500 2,097.66 -10.12 -0.48%
NASDAQ 4,965.7940 -14.1070 -0.28%

Nicole's Tweets

Brokerage Partners

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs